Investigation of the effects of Longvida on cognitive functions in a healthy population: a double-blind, randomized placebo-controlled and parallel study

Not Applicable

• Conditions: decline of cognitive function

• Registration Number: JPRN-UMIN000022128
• Lead Sponsor: HUMA R&D Co.

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2016-05-02
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

Not provided

Exclusion Criteria

1)Patients under medical treatment 2)Patients under dietetic treatment or ergotherapy 3)Subjects who have previous medical history and/or current medical history of serious diseases (e.g., liver, kidney, endocrine, cardiovascular system, digestive organ, lung, blood, and/or metabolism). 4)Subjects who have undergone gastrointestinal tract surgery; except appendectomy. 5)Subjects who have previous medical history and/or current medical history of mental disorder. 6)Subjects who have previous medical history of drug and/or food allergy. 7)Subjects who have previous medical history and/or current medical history of drug dependence and/or drug abuse. 8)Subjects who participate in other clinical trial within a month 9)Subjects who work time is irregular. 10)Subjects who have previous medical history and/or current medical history of alcoholism 11)Subjects who are in receipt of public assistance 12) Subjects who have been determined ineligible by principal investigator or sub-investigator.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Repeatable Battery for the Assessment of Neuropsychological Status Hasegawa dementia rating scale

Secondary Outcome Measures

Name	Time	Method
Subjective symptoms: intake 0, 2, 4, 6, 8, 10, 12 weeks Safety(blood test, history taking):intake 0, 12 weeks